BE Therapeutics Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$2.6M
- Investors
-
8
BE Therapeutics General Information
Description
Developer of regenerative medicine therapies designed to repair and restore damaged brain and spinal cord tissue. The company's technology focuses on engineering functional tissue and treating neurological conditions and spinal cord injuries with a novel approach, enabling healthcare institutions to improve patient outcomes.
Contact Information
Website
www.betherapeutics.comCorporate Office
- 1410 Pelham Parkway South Bronx
- Kennedy 715
- New York, NY 10461
- United States
Corporate Office
- 1410 Pelham Parkway South Bronx
- Kennedy 715
- New York, NY 10461
- United States
BE Therapeutics Timeline
BE Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Seed Round | 19-Mar-2025 | $2.6M | Completed | Generating Revenue | ||
| 2. Seed Round | 07-Mar-2024 | Completed | Generating Revenue | |||
| 1. Seed Round | 22-Nov-2023 | $3.6M | $3.6M | Completed | Generating Revenue |
BE Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
BE Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BE Therapeutics Patents
BE Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025245484-A1 | Foxn1 activators | Pending | 23-May-2024 | ||
| WO-2025245461-A1 | Methods of activating foxn1 | Pending | 23-May-2024 |
BE Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BE Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alumni Ventures | Venture Capital | Minority | ||
| Apollo Health Ventures | Venture Capital | Minority | ||
| Empire State Development | Government | Minority | ||
| Healthspan Capital | Venture Capital | Minority | ||
| Longevitytech.fund | Venture Capital | Minority |
BE Therapeutics FAQs
-
When was BE Therapeutics founded?
BE Therapeutics was founded in 2023.
-
Where is BE Therapeutics headquartered?
BE Therapeutics is headquartered in New York, NY.
-
What is the size of BE Therapeutics?
BE Therapeutics has 4 total employees.
-
What industry is BE Therapeutics in?
BE Therapeutics’s primary industry is Biotechnology.
-
Is BE Therapeutics a private or public company?
BE Therapeutics is a Private company.
-
What is BE Therapeutics’s current revenue?
The current revenue for BE Therapeutics is .
-
How much funding has BE Therapeutics raised over time?
BE Therapeutics has raised $6.2M.
-
Who are BE Therapeutics’s investors?
Alumni Ventures, Apollo Health Ventures, Empire State Development, Healthspan Capital, and Longevitytech.fund are 5 of 8 investors who have invested in BE Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
